|
- Regorafenib - Wikipedia
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK) Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
- Regorafenib Uses, Side Effects Warnings - Drugs. com
What is regorafenib? Regorafenib is used to treat colorectal cancer and liver cancer It is also used to treat a rare type of tumor that can affect the esophagus, stomach, or intestines Regorafenib is usually given after other cancer medications have been tried without success
- Regorafenib - NCI - National Cancer Institute
Regorafenib is a type of targeted therapy drug called a kinase inhibitor It is a small-molecule drug (a drug that can enter cells easily) FDA label information for this drug is available at DailyMed Regorafenib is approved to treat: Colorectal cancer that has spread to other parts of the body
- Regorafenib (oral route) - Mayo Clinic
Regorafenib is used to treat metastatic cancer (cancer that has spread) of the colon and rectum It is used in patients who have already been treated with other cancer medicines that did not work well Regorafenib prevents the growth of tumors
- Regorafenib (Stivarga) | Cancer information - Cancer Research UK
Regorafenib is a type of targeted drug It is a treatment for bowel, liver and gastro intestinal stromal cancer (GIST) Find out what regorafenib is, about how you have it, possible side effects and other important information about taking regorafenib
- STIVARGA® (regorafenib) | Patient Website
STIVARGA is a once-daily, oral prescription anticancer medicine approved by the FDA for people with mCRC, GIST, and HCC CRC that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines
- STIVARGA (regorafenib) Label - Food and Drug Administration
Stivarga® is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and
- Stivarga (regorafenib) dosing, indications, interactions, adverse . . .
Indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based
|
|
|